コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 fidobacterium was negatively associated with 5-hydroxytryptamine.
2 greater solution stability than alpha-methyl-5-hydroxytryptamine.
4 fibroblast growth factor receptor 1 (FGFR1)-5-hydroxytryptamine 1A (5-HT1A) receptor complexes have
5 e altered through serotonergic modulation of 5-hydroxytryptamine 1A (5-HT1A) receptors, which hyperpo
7 ve agonist radioligand for the serotonin 1A (5-hydroxytryptamine 1A [5-HT1A]) receptor in recombinant
9 ctivation of G(i), by comparing Smo with the 5-hydroxytryptamine(1A) (5-HT(1A)) receptor, a quintesse
10 e measurement of activation of the serotonin 5-hydroxytryptamine-1A (5-HT(1A)) receptor expressed in
12 l evidence implicates the serotonin receptor 5-hydroxytryptamine 1B (5-HT1B) in the effects of cocain
14 sly that GSK3beta selectively interacts with 5-hydroxytryptamine-1B receptors (5-HT1BR) that have imp
16 mbled as a GPCR heteromer with the serotonin 5-hydroxytryptamine 2A (5-HT(2A)) receptor in the mouse
20 s of neuroscience and clinical research into 5-Hydroxytryptamine 2A (5-HT2A) receptor agonists, such
22 The D2 dopamine receptor and the serotonin 5-hydroxytryptamine 2A receptor (5-HT2A) are closely-rel
25 al gene expression patterns of the 5-HT(2A) (5-hydroxytryptamine 2A) and 5-HT(1A) (5-hydroxytryptamin
27 ribosomal S6 kinase 2 (RSK2) interacts with 5-hydroxytryptamine(2A) (5-HT(2A)) serotonin receptors a
30 ies suggest that cis-UCA binds to serotonin (5-hydroxytryptamine) 2A (5-HT(2A)) receptor and that ant
31 blocked by SB742457 but not by the selective 5-hydroxytryptamine-2A (5HT2A) antagonist ketanserin) an
32 e on the postsynaptic serotonin-2A receptor (5-hydroxytryptamine-2A, or 5-HT2A) status were investiga
33 ion structure of a complex between the human 5-hydroxytryptamine 2B (5-HT2B) receptor and an antibody
34 assessed whether these polymorphisms affect 5-hydroxytryptamine 2B (5-HT2B) receptor in vitro pharma
35 ulatory function requires stimulation of the 5-hydroxytryptamine 2B receptor (5-HT(2B)) on HSCs by se
36 hat they and/or their metabolites are potent 5-hydroxytryptamine(2B) (5-HT(2B)) receptor agonists.
37 e intensity arising from fluorescence-tagged 5-hydroxytryptamine 2C (5-HT(2C)) receptors diffusing wi
38 express an eGFP-tagged form of the serotonin 5-hydroxytryptamine 2C (5-HT2C) receptor, global analysi
43 ethod is based on the serotonin 2C receptor (5-hydroxytryptamine(2C); 5HT(2C)) transcript, an RNA edi
44 other compared the relative efficacy of the 5-hydroxytryptamine-3 (5-HT(3)) receptor antagonists.
46 K1] receptor antagonist) and palonosetron (a 5-hydroxytryptamine-3 [5-HT3] receptor antagonist) for t
47 V management up to 72 h with the long-acting 5-hydroxytryptamine-3 receptor antagonist palonosetron.
49 tosensory cortex of the mouse, the serotonin 5-hydroxytryptamine 3A (5-HT(3A)) receptor, the only ion
50 ple all-atom MD simulations of the homomeric 5-hydroxytryptamine 3A (5-HT(3A)) serotonin receptor for
51 ) has greater potency at mouse than at human 5-hydroxytryptamine 3A (5-HT3A) receptors, despite 84% a
52 domain 2 (TM2) to the TM2-TM3 loop, in mouse 5-hydroxytryptamine(3A) (5-HT(3A)) receptor function was
53 lated manner(4) by enzymatic conversion from 5-hydroxytryptamine (5-HT or serotonin), and modulates s
54 observe the dynamic binding and unbinding of 5-hydroxytryptamine (5-HT) (i.e., serotonin) to the bind
57 development of a PET radioligand for imaging 5-hydroxytryptamine (5-HT) 6 receptors in the brain woul
59 rrent activated by maximal concentrations of 5-hydroxytryptamine (5-HT) and increased the magnitude o
60 cted segments of native mouse intestine with 5-hydroxytryptamine (5-HT) and prostaglandin E2 (PGE2) i
62 ough there is general agreement that mucosal 5-hydroxytryptamine (5-HT) can initiate peristaltic refl
63 rn blot, whereas tryptophan, kynurenine, and 5-hydroxytryptamine (5-HT) concentrations were quantifie
66 transport protein which re-uptakes excessive 5-hydroxytryptamine (5-HT) from effective location to te
68 r (SERT) is responsible for the re-uptake of 5-hydroxytryptamine (5-HT) from the synaptic cleft after
70 lum) revealed significantly higher levels of 5-hydroxytryptamine (5-HT) in the striatum and hippocamp
71 ulation of cultured smooth muscle cells with 5-hydroxytryptamine (5-HT) induced PAK1 phosphorylation
78 ring reversal learning, whilst orbitofrontal 5-hydroxytryptamine (5-HT) likely mediates this type of
79 resent studies examined the acute effects of 5-hydroxytryptamine (5-HT) on NHE activity using Caco-2
84 read use of short-acting antagonists for the 5-hydroxytryptamine (5-HT) receptor, about 50% of patien
85 ty for beta-arrestin signaling at the 5-HT2B 5-hydroxytryptamine (5-HT) receptor, whereas they are re
86 entify that both ionotropic and metabotropic 5-hydroxytryptamine (5-HT) receptors are expressed on wh
87 duced inactivation and reactivation of human 5-hydroxytryptamine (5-HT) receptors in a recombinant ce
89 gene (Itgb3) on SERT function and selective 5-hydroxytryptamine (5-HT) reuptake inhibitor (SSRI) eff
90 rter inhibitor Prozac, the inhibition of the 5-hydroxytryptamine (5-HT) transporter by the ion channe
91 PKM Apl III in the sensory neuron 2 d after 5-hydroxytryptamine (5-HT) treatment reversed persistent
95 ted Sf9 cells, we show the inhibition of [3H]5-hydroxytryptamine (5-HT) uptake and [3H]dihydrotetrabe
96 , mucus release stimulated by either PGE2 or 5-hydroxytryptamine (5-HT) was approximately half that s
99 T function in vivo led to reduced serotonin (5-hydroxytryptamine (5-HT)) blood levels that paralleled
100 ut microbiota regulates levels of serotonin (5-hydroxytryptamine (5-HT)) in the intestinal epithelium
104 napse is dynamically regulated by serotonin (5-hydroxytryptamine (5-HT)) with elevated levels leading
105 d to elevated levels of embryonic serotonin (5-hydroxytryptamine (5-HT)), and we found that knockdown
112 ce Na(+) for driving transport and promoting 5-hydroxytryptamine (5-HT)-dependent conformational chan
115 ggression in golden hamsters is inhibited by 5-hydroxytryptamine (5-HT)1A receptors and facilitated b
117 that acute stressors can increase serotonin [5-hydroxytryptamine (5-HT)] concentrations in the dorsom
118 body of literature has implicated serotonin [5-hydroxytryptamine (5-HT)] in descending modulation of
122 The dynamic interplay between serotonin [5-hydroxytryptamine (5-HT)] neurotransmission and the hy
124 ncoded Ile, Asn, and Ile (INI) of serotonin [5-hydroxytryptamine (5-HT)] receptor 2C (5-HT(2C)R) with
125 vidence that cis-UCA binds to the serotonin [5-hydroxytryptamine (5-HT)] receptor with relatively hig
132 the foremost hypothesis of depression is the 5-hydroxytryptamine (5-HT, serotonin) deficiency hypothe
133 with a prenatal, genetically induced loss of 5-hydroxytryptamine (5-HT, serotonin) neurones are compr
134 e have found that the serotonin 1B receptor [5-hydroxytryptamine (5-HT1B) receptor] interacts with p1
135 is was reversed by systemic treatment with a 5-hydroxytryptamine (5-HT2C) receptor agonist and mimick
136 ression in the central nervous system (CNS), 5-hydroxytryptamine (5-HT: serotonin) subtype 6 receptor
137 is responsible for reuptake and recycling of 5-hydroxytryptamine (5-HT; serotonin) after its exocytot
140 e and some other transmitters, estimation of 5-hydroxytryptamine (5-HT; Serotonin) release has proved
141 ation studies suggest that variations in the 5-hydroxytryptamine (5-HT; serotonin) transporter (5-HTT
144 ays a critical role in regulating serotonin (5-hydroxytryptamine [5-HT]) availability in the gut.
146 We tested the hypothesis that serotonin (5-hydroxytryptamine [5-HT]) exerts stimulatory and inhib
148 s suggested an important role for serotonin (5-hydroxytryptamine [5-HT]) in enhancing the counterregu
154 different pruritogens, including serotonin (5-hydroxytryptamine [5-HT]), histamine, SLIGRL (protease
161 steroid (AAS) exposure and brain serotonin (5-hydroxytryptamine, 5-HT) depletion on behavior of pube
162 e as induced by an increase in serotonergic (5-hydroxytryptamine, 5-HT) efficacy has been a target of
163 associated with abnormalities in serotonin (5-hydroxytryptamine, 5-HT) in regions of the brainstem c
164 cleus (DR) is the major source of serotonin (5-hydroxytryptamine, 5-HT) in the forebrain and dysfunct
170 ong RVM neurons, we found that serotonergic (5-hydroxytryptamine, 5-HT) neurons decreased by 35% ipsi
172 paration to examine the effect of serotonin (5-hydroxytryptamine, 5-HT) receptor activation on segmen
173 aphe nuclei and expresses several serotonin (5-hydroxytryptamine, 5-HT) receptor subtypes, including
175 l trafficking of single groups of serotonin (5-hydroxytryptamine, 5-HT) receptors using single quantu
176 ine oxidase (MAOIs) and selective serotonin (5-hydroxytryptamine, 5-HT) reuptake (SSRIs) induces sero
181 osed mice had reduced contents of serotonin (5-hydroxytryptamine, 5-HT), a neurotransmitter involved
182 tract contains much of the body's serotonin (5-hydroxytryptamine, 5-HT), but mechanisms controlling t
186 MAO A), the key enzyme catalyzing serotonin (5-hydroxytryptamine; 5-HT) and norepinephrine (NE) degra
187 The monoamine neurotransmitter serotonin (5-hydroxytryptamine; 5-HT) exerts an inhibitory influenc
189 raphe nucleus, which provides serotonergic (5-hydroxytryptamine; 5-HT) innervation to the nucleus ac
193 eory is that a breakdown in brain serotonin (5-hydroxytryptamine; 5-HT) signalling is critically invo
197 the source of nearly all systemic serotonin (5-hydroxytryptamine; 5-HT), which is an important neurot
198 the source of nearly all systemic serotonin (5-hydroxytryptamine; 5-HT), which is an important neurot
204 s its role as a neurotransmitter, serotonin (5-hydroxytryptamine, 5HT) regulates inflammation and tis
207 thylamide (LSD) binding to recombinant human 5-hydroxytryptamine 6 (5-HT(6)) receptors expressed in C
208 onship (QSAR) models of compounds binding to 5-hydroxytryptamine-6 receptor (5-HT(6)R), a known targe
210 3-(piperazinylmethyl) indole derivatives as 5-hydroxytryptamine-6 receptor (5-HT6R) antagonists resu
211 ave previously reported on the unusual human 5-hydroxytryptamine(7) (h5-HT(7)) receptor-inactivating
212 scratching was observed following i.d. 5-HT (5-hydroxytryptamine), a protease-activated receptor (PAR
213 l that a distinct multiprotein complex links 5-hydroxytryptamine-activated intracellular signaling ev
214 T) is responsible for reuptake of serotonin (5-hydroxytryptamine) after its exocytotic release from n
215 meostasis, such as the melanocortin, leptin, 5-hydroxytryptamine and brain-derived neurotrophic facto
216 ated release of the peristaltic transmitters 5-hydroxytryptamine and calcitonin gene-related peptide;
217 lls, and platelet aggregation and release of 5-hydroxytryptamine at the colonic mucosae were common i
218 uced by acidic citrate, but not alpha-methyl-5-hydroxytryptamine, chloroquine, compound 48/80, or bil
219 l mucosal reflexes, which release serotonin (5-hydroxytryptamine) from enterochromaffin cells, and st
220 f single conformations of neutral serotonin (5-hydroxytryptamine) have been studied in the gas phase
221 eptide Y Y2 receptor (NPY(2)R) and serotonin 5-hydroxytryptamine (HT)(2C) receptor (5-HT(2C)R) to cil
223 ng a variety of cellular signals elicited by 5-hydroxytryptamine in both peripheral and central tissu
224 racellular dopamine in prefrontal cortex and 5-hydroxytryptamine in hippocampus, compared with their
225 ellular signals elicited by serotonin (5-HT; 5-hydroxytryptamine) in both peripheral and central tiss
226 monoamine neurotransmitter serotonin (5-HT, 5-hydroxytryptamine) in the central nervous system, and
228 ke of the neurotransmitter, serotonin (5-HT; 5-hydroxytryptamine), into cells by the 5-HT transporter
229 he MAOA-L, by causing an ontogenic excess of 5-hydroxytryptamine, labilizes critical neural circuitry
232 , the mutant SNAP-25 could no longer support 5-hydroxytryptamine-mediated inhibition of exocytosis.
233 stigated the effect of diminished serotonin (5-hydroxytryptamine) neurotransmission using dietary try
234 significantly elevated levels of serotonin (5-hydroxytryptamine), norepinephrine, dopamine, and beta
236 electroactive chemical messenger serotonin (5-hydroxytryptamine or 5-HT) for the real-time measureme
239 mall molecules, we identified the serotonin (5-hydroxytryptamine or 5-HT) receptor antagonist metitep
241 aptic (type III) cells to release serotonin (5-hydroxytryptamine, or 5-HT) and norepinephrine (NE).
246 e not observed in response to acetylcholine, 5-hydroxytryptamine, or the protease-activated receptor-
247 ated and produced soluble factors serotonin (5-hydroxytryptamine), platelet factor 4, and platelet-ac
250 rmal unfolding of a homopentameric LGIC, the 5-hydroxytryptamine receptor (ligand binding, secondary
251 The objective of this study was to compare 5-hydroxytryptamine receptor 1A (5-HT(1A)) PET with cere
253 paper addresses whether the availability of 5-hydroxytryptamine receptor 1B (5-HT(1B)) is seen to de
254 , around 500 kb upstream of the locus HTR1E (5-hydroxytryptamine receptor 1E) locus, related to the s
255 rC11, histamine receptor H1, IL-31 receptor, 5-hydroxytryptamine receptor 1F, natriuretic precursor p
256 e can result from the abrupt withdrawal of a 5-hydroxytryptamine receptor 2A antagonist from a treatm
257 appa-opioid receptors or blockade of 5-HT2A (5-hydroxytryptamine receptor 2A) receptors, suppressed m
259 tion studies linking the c.68C allele of the 5-hydroxytryptamine receptor 2C gene to lower seizure ri
263 ynthesis in the brain-and serotonin receptor 5-hydroxytryptamine receptor 6 (HTR6) are crucial in med
264 e, and administration of dexamethasone and a 5-hydroxytryptamine receptor antagonist such as ondanset
266 of the G alpha(q)-linked serotonin receptor 5-hydroxytryptamine receptor-2b (Htr2b) in maternal isle
269 istic receptors of enteric neurons, Ret, and 5-hydroxytryptamine-receptor subtypes at 33 degrees C an
270 ide Y, vasoactive intestinal peptide, or the 5-hydroxytryptamine (serotonin) 3a receptor, were silent
271 work directly on the SNARE complex, such as 5-hydroxytryptamine (serotonin) 5-HT(1b) receptors and a
273 is a selective, high-affinity agonist of the 5-hydroxytryptamine (serotonin) receptor 4 that enhances
274 rescent photoproducts of the hydroxyindoles, 5-hydroxytryptamine (serotonin), 5-hydroxytrptophan, and
275 )/Cl(-)-dependent transporters for dopamine, 5-hydroxytryptamine (serotonin), noradrenaline, GABA and
276 litation (LTF) of sensory neuron synapses by 5-hydroxytryptamine (serotonin; 5-HT) requires the activ
277 yV internalization is dependent on serotonin 5-hydroxytryptamine subfamily 2 receptors (5-HT(2)Rs), a
278 ety of new antiemetic medications, primarily 5-hydroxytryptamine subtype 3 receptor antagonists, as w
281 ect an influence of natural variation in the 5-hydroxytryptamine transporter (5-HTT) gene on multiple
282 the gene encoding the serotonin transporter [5-hydroxytryptamine transporter (5-HTT)] affect the tran
283 ned treatment of C6 glioma cells, which lack 5-hydroxytryptamine transporters, showed marked concentr
284 race amine-associated receptor 1 (TAAR1) and 5-hydroxytryptamine type 1A (5-HT(1A)) receptors, may re
285 by spinal delivery of duloxetine acting via 5-hydroxytryptamine type 2A receptors and temporally coi
286 transmembrane domain (M3) is conserved among 5-hydroxytryptamine type 3 (5-HT(3)) receptor subunits a
290 this article, we discuss the pharmacology of 5-hydroxytryptamine type 3 receptor antagonists and the
291 atients may help differentiate responders to 5-hydroxytryptamine type 3 receptor antagonists from non
294 te-binding cassette subfamily B member 1 and 5-hydroxytryptamine type 3 receptor subunits also contri
295 ily of pentameric ligand-gated ion channels, 5-hydroxytryptamine type 3 receptors (5-HT3Rs) are activ
296 ethasone, aprepitant or fosaprepitant, and a 5-hydroxytryptamine type 3-receptor antagonist, in patie
297 rg(436) and Arg(440)) within the MA helix of 5-hydroxytryptamine type 3A (5-HT3A) receptors act singu